COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025 -
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed -
COMMUNIQUÉ DE PRESSE
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
New analysis shows Xifaxan efficacy in reducing OHE rehospitalizations regardless of prior treatment. Data presented at DDW 2025 -
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing -
-
COMMUNIQUÉ DE PRESSE
E-Cite Motors to Expand U.S. Manufacturing and Increase Domestic Component Sourcing Amid Favorable Economic Conditions and Rising Tariffs
E-Cite expands US production of key vehicle components for RJ, RT, and GT models in response to tariffs and economic trends, emphasizing American innovation and market growth -
-
